Trial reportSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2026
Effectiveness and Safety of a Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial Study.
Trial report in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Safety of a Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial Study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundErythematotelangiectatic rosacea is a chronic recurrent inflammatory disease that often impose a significant psychological burden on patients. Given that effective moisturization is integral to its management, the choice of a proper moisturizer is a critical clinical consideration. Our study aims to assess the effectiveness and safety of a moisturizer containing Centella asiatica extract, ceramide NP, and panthenol for erythema and skin barrier in Chinese patients with erythematotelangiectatic rosacea.
methodsAll enrolled patients were prescribed oral minocycline 50 mg once daily and applied moisturizer twice daily. Facial images of facial redness, stratum corneum hydration (SCH), transepidermal water loss (TEWL), and Clinician's Erythema Assessment (CEA) were collected at baseline, day 7 (D7), day 14 (D14), and day 28 (D28). Time to a 1-point reduction in the Patient's Self-Assessment (PSA) scale and Rosacea-specific Quality-of-life instrument (RosQol) were also recorded by patients.
resultsA total of 75 patients with rosacea were enrolled, 39 patients were randomized to the experimental group and 36 to the control group. Our study showed that the variations of a* value, facial red area, SCH and RosQol from baseline to D28 were rapidly and significantly greater in the experimental group, and the mean rank of CEA was significantly higher in the control group at D28. All AEs were mild and self-limiting.
conclusionsThis study found that the moisturizer containing Centella asiatica extract, ceramide NP, and panthenol delivers rapid, effective adjunctive benefits in rosacea treatment and represents a reliable daily skincare option for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.